跳至主要内容
临床试验/NCT06680011
NCT06680011招募中不适用

Cohort-Based Study of Diagnostic Biomarkers for Neurosyphilis

Shanghai Mental Health Center1 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2024年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
360
试验地点
1
主要终点
Measurement of AIM2 inflammasome in peripheral blood.

研究概览

简要总结

The goal of this observational study is to identify diagnostic biomarkers for neurosyphilis in patients with the condition. The main questions it aims to answer are:

What plasma biomarkers are associated with neurosyphilis? What electrophysiological characteristics (EEG and eye movement) are linked to neurosyphilis? Researchers will compare biomarker data from plasma and gut microbiome analyses with electrophysiological findings to see if these factors can help diagnose neurosyphilis.

Participants will:

Provide clinical information such as age, gender, symptoms, and disease course Submit blood and urine samples for proteomics and metagenomic sequencing Undergo EEG and eye movement evaluations for electrophysiological analysis

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Neurosyphilis Patients
  • Meet the diagnostic criteria for neurosyphilis in this study based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).
  • Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).
  • At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.
  • No contraindications for electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).
  • Non-neurosyphilis Syphilis Patients
  • Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests.
  • Does not meet the diagnostic criteria for neurosyphilis in this study, based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum and rapid plasma reagin tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).
  • Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).
  • At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.
  • No contraindications for electroencephalogram (EEG).
  • Healthy Controls
  • Physically healthy (no mental illnesses or diseases affecting bodily organs).
  • Aged 18-65 years, regardless of gender.
  • At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.
  • No contraindications for electroencephalogram (EEG).

排除标准

  • Neurosyphilis Patients & Non-neurosyphilis Syphilis Patients
  • Age < 18 years or > 65 years;
  • Pregnant or breastfeeding women (female patients are rare in clinical practice);
  • HIV-positive;
  • Presence of severe primary diseases (such as liver, kidney, endocrine, or hematological diseases) accompanied by autoimmune diseases or connective tissue diseases;
  • Presence of other central nervous system diseases besides neurosyphilis;
  • Contraindications for transcranial magnetic stimulation (TMS) treatment, such as history of head trauma, epilepsy, or presence of metal implants;
  • Contraindications for electroencephalography (EEG), such as severe scalp injuries, extensive or open cranial trauma, inability to place electrodes, or potential for infection from the examination.
  • Education level below junior high school.
  • Healthy Controls
  • Age < 18 years or > 65 years;
  • Pregnant or breastfeeding women;
  • HIV-positive;
  • Other central nervous system diseases, severe physical illnesses, or major organ diseases;
  • Presence of severe primary diseases (such as liver, kidney, endocrine, or hematological diseases) accompanied by autoimmune diseases or connective tissue diseases;
  • Contraindications for electroencephalography (EEG), such as severe scalp injuries, extensive or open cranial trauma, inability to place electrodes, or potential for infection from the examination;
  • Education level below junior high school.

结局指标

主要结局

Measurement of AIM2 inflammasome in peripheral blood.

时间窗: Data will be collected at baseline, 6 months, and 12 months after enrollment.

This measure will assess the expression levels of the AIM2 inflammasome in peripheral blood samples from subjects using proteomics methods, mass spectrometry.

Measurement of NFL and sTREM2 in cerebrospinal fluid.

时间窗: Data will be collected at baseline, 6 months, and 12 months after enrollment.

This measure will evaluate the levels of neurofilament light chain (NFL) and myeloid cells 2 (sTREM2) in cerebrospinal fluid samples from subjects. The measurement will utilize techniques such as TRUST, TPPA and mass spectrometry to assess these biomarkers.

次要结局

  • Assessment of Cognitive Function using MoCA(Cognitive assessments will be conducted at baseline and 6 months post-enrollment.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验